Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor

US9949971B2 · kind B2 · utility

Assignee

• Acerta Pharma B.V. · NL

Inventors

• Ahmed Hamdy · Santa Cruz, US
• Wayne Rothbaum · New York, US
• Raquel Izumi · Redwood City, US
• Brian Lannutti · Solana Beach, US
• Todd Covey · Redwood City, US
• Roger Ulrich · Köniz, CH
• Dave Johnson · Capitola, US
• Tjeerd Barf · Ravenstein, NL
• Allard Kaptein · Zaltbommel, NL

Key dates

• Filing date: Jun 17, 2015
• Grant date: Apr 24, 2018
• Expiry date: Jun 17, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/732
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a PI3K-δ inhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, PI3K-δ inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.